Skip to NavigationSkip to content

Gilead

Novartis becomes first to gain second CAR T indication

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of treatment.

The approval brings Kymriah into the same market space occupied by Gilead’s rival treatment, Yescarta. Most importantly for Novartis, It opens up a new patient pool and will see sales of the drug increase, after a sluggish start to life on the market.

US court upholds verdict voiding MSD's claim to $200m from Gilead in patent dispute

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly obtained patent rights for the treatment of hepatitis C, voiding its claim to an infringement verdict against Gilead to the tune of $200 million.

New hepatitis C combo boasts 97% cure rate for just $300

Image Credit: BruceBlaus

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working to bring a new, effective and affordable combination therapy to patients with hepatitis C (HCV).

New Chief Science and Medical Officers for Gilead

Published on: 19/03/18

Gilead has announced that Dr Norbert Bischofberger, its Chief Scientific Officer (CSO), Executive Vice President of Research and Development and a veteran of almost 30 years at the company, will be leaving his position at the end of April. He will be succeeded by Dr John McHutchison (pictured), who will step up from his current role as Executive Vice President of Clinical Research to assume the mantle of CSO as well as responsibility for Gilead’s R&D organisation.

Top Ten most popular articles on Pharmafile.com this week

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter here in the UK. So there's the hope that Spring is just around the corner as we pass another Friday and another top ten rundown of the week's most popular articles.

Switching to Gilead's Biktarvy proves non-inferior in HIV patients

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from a range of regimens.

Gilead investigational data gives hope for HIV eradication in humans

Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational oral toll-like receptor 7 (TLR7) agonist, and the broadly neutralising antibody (bNAb) PGT121, in the eradication of HIV in non-human primates.

Gilead seals $3bn deal, hoping for off-the-shelf CAR-T

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high cost of the treatments; now, the next step in the field is to find a way to speed up this process, whoever gets there first will have a big advantage.

With this in mind, Gilead has signed a deal with Sangamo Therapeutics that could be worth over $3 billion for the latter company, in a bid to strengthen its acquisition of Kite to gain a position on the market.

Long-running, $2.5bn lawsuit swings in Gilead’s favour

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, when a record fine is looming over a company, it can also be dependent on the court rooms.

Gilead will be breathing a sigh of relief, after a judge overturned a record $2.54 billion decision against it. The case was brought by MSD, known as Merck in North America, regarding Gilead’s blockbuster hepatitis C drugs, Sovaldi and Harvoni.

MSD had alleged that Gilead infringed its patents and had initially won the case in December of 2016.

FDA approves Gilead's Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches